Bharat Immunological & Biologicals Corporation Share Price
₹32.21 +1.89 (6.23%)
08 Jan, 2025 03:59
Start SIP in BIBCL
Start SIPPerformance
- Low
- ₹0
- High
- ₹0
- 52 Week Low
- ₹0
- 52 Week High
- ₹0
- Open Price₹0
- Previous Close₹0
- Volume0
Investment Returns
- Over 1 Month + 24.56%
- Over 3 Month + 17.38%
- Over 6 Month + 8.49%
- Over 1 Year -8.99%
Smart Investing Starts Here Start SIP with Bharat Immunological & Biologicals Corporation for Steady Growth!
Bharat Immunological & Biologicals Corporation Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
Bharat Immunological & Biologicals Corporation Financials
Bharat Immunological & Biologicals Corporation Technicals
EMA & SMA
Current Price
₹32.21
+
1.89
(6.23%)
- Bullish Moving Average 16
- Bearish Moving Average 0
- 20 Day
- ₹25.66
- 50 Day
- ₹25.46
- 100 Day
- ₹26.33
- 200 Day
- ₹27.39
Resistance and Support
33.4
- R3 38.69
- R2 37.28
- R1 34.81
- S1 30.93
- S2 29.52
- S3 27.05
Bharat Immunological & Biologicals Corporation Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-08-16 | General Purpose. | |
2024-03-08 | Others | General Purpose |
2023-10-31 | Quarterly Results | |
2023-04-24 | Audited Results | |
2023-02-09 | Quarterly Results |
Bharat Immunological & Biologicals Corporation F&O
About Bharat Immunological & Biologicals Corporation
- NSE Symbol
- BIBCL
- BSE Symbol
- 524663
- ISIN
- INE994B01014
Similar Stocks to Bharat Immunological & Biologicals Corporation
Bharat Immunological & Biologicals Corporation FAQs
Bharat Immunological & Biologicals Corporation share price is ₹32 As on 08 January, 2025 | 03:45
The Market Cap of Bharat Immunological & Biologicals Corporation is ₹139.1 Cr As on 08 January, 2025 | 03:45
The P/E ratio of Bharat Immunological & Biologicals Corporation is -7.5 As on 08 January, 2025 | 03:45
The PB ratio of Bharat Immunological & Biologicals Corporation is 1.6 As on 08 January, 2025 | 03:45
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.